Enliven Therapeutics, Inc. (ELVN)
| Market Cap | 2.81B +222.8% |
| Revenue (ttm) | n/a |
| Net Income | -98.78M |
| EPS | -1.65 |
| Shares Out | 60.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,146,000 |
| Open | 39.77 |
| Previous Close | 40.36 |
| Day's Range | 39.00 - 47.36 |
| 52-Week Range | 14.79 - 48.53 |
| Beta | 0.40 |
| Analysts | Strong Buy |
| Price Target | 60.11 (+30.31%) |
| Earnings Date | May 7, 2026 |
About ELVN
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and othe... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ELVN stock is "Strong Buy." The 12-month stock price target is $60.11, which is an increase of 30.31% from the latest price.
News
Why Is Enliven Therapeutics Stock (ELVN) Up Today?
Enliven Therapeutics stock was up on news of an upsized public offering.
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and developmen...
Enliven announces $250M common stock offering
Enliven (ELVN) Therapeutics announced that it has commenced an underwritten public offering of $250M of shares of its common stock and, in lieu of common stock to investors who so…
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and developmen...
Enliven Therapeutics Transcript: Study update
ELVN-001, a highly selective ATP-competitive BCR-ABL1 TKI, showed strong efficacy and a favorable safety profile in heavily pretreated CML patients, including those with prior asciminib exposure. Phase III trials are set to begin, aiming to establish best-in-class status across multiple lines of therapy.
Enliven Therapeutics Press release: Study update
Enliven Therapeutics issued a press release on June 11, 2026, disclosing material business information to investors.
Enliven Therapeutics Slides: Study update
Enliven Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 11, 2026.
Enliven up 15% to $42.50 after positive data from Phase 1 ENABLE trial
08:15 EDT Enliven (ELVN) up 15% to $42.50 after positive data from Phase 1 ENABLE trial
Enliven’s ELVN-001 shows efficacy in Phase 1 myeloid leukemia trial
Enliven (ELVN) Therapeutics presented updated positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with previously treated chronic myeloid leukemia, or CML. The company...
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
61% overall MMR and 48% MMR achievement by 24 weeks in the 80 mg QD Phase 1b cohort 67% overall MMR and 55% MMR achievement by 24 weeks in all Phase 1b patients who had previously received 1 or 2 prio...
Enliven initiated with a Buy at Stifel
Stifel initiated coverage of Enliven (ELVN) with a Buy rating and $60 price target The company’s ELVN-001 is “uniquely positioned” as a complement to allosteric inhibitors like Scemblix in the…
Enliven Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing a highly specific BCR-ABL1 TKI for CML, with updated phase I data to be presented at EHA. Plans are in place for a pivotal second-line plus trial, with regulatory meetings expected mid-year and top-line data anticipated in early 2029. Cash reserves support operations through key milestones.
Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress
Enliven will host a webcast conference call on June 11, at 8:30 a.m. ET BURLINGAME, Calif.
Enliven price target raised to $62 from $45 at Mizuho
Mizuho raised the firm’s price target on Enliven (ELVN) to $62 from $45 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q1…
Enliven Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
The company is advancing ELVN-001 for CML, with strong phase I data and a pivotal trial in second-line-plus CML planned for later this year. The drug shows a favorable safety and efficacy profile, is positioned to address resistance after asciminib, and has a cash runway into 2029.
Enliven Therapeutics to Present at Upcoming Investor Conferences
BOULDER, Colo., May 21, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of ...
Enliven to presents Phase 1 clinical trial data for ELVN-100 at EHA Congress
Enliven (ELVN) Therapeutics announced additional data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia in an abstract accepted for an oral presentat...
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated 80 mg QD Phase 1b cohort In patients who previously ...
Guggenheim starts Enliven with Buy on leukemia opportunity
Guggenheim last night initiated coverage of Enliven (ELVN) with a Buy rating and $80 price target The company is focused on the discovery and development of small molecule therapeutics, the…
Enliven initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Enliven (ELVN) with a Buy rating and $80 price target
Enliven price target raised to $59 from $41 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Enliven (ELVN) to $59 from $41 and keeps a Buy rating on the shares. Enliven reported Q1 results and reaffirmed timelines for…
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Phase 1 data update for ELVN-001 expected mid-2026 Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026 Strong balance sheet with $452 million in cash, cash...
Enliven Therapeutics Quarterly report: Q1 2026
Enliven Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.